You are here
P&T June 2015
State and national professional and regulatory bodies are focusing on opioid drug abuse by upgrading requirements for health care practitioners to ensure that all controlled substances are prescribed and dispensed for legitimate medical purposes.
Pain modulation is a key treatment goal for diabetic peripheral neuropathy patients. Guidelines have recommended antidepressant, anticonvulsant, analgesic, and topical medications—both approved and off-label—to reduce pain in this population.
Medications are often added to behavioral therapy to help patients with autism spectrum disorder function successfully. This review discusses approved and off-label pharmacotherapeutic options for the various symptoms of the disorder.
Notable sessions at the American Academy of Dermatology meeting focused on pediatric eczema, infantile hemangiomas, and vaccines.
The 2015 Aging in America Conference featured discussions on managing medication use in elderly patients.
Potential blockbuster therapies, such as proprotein convertase subtilisin/kexin type 9 inhibitors, are expected to revolutionize dyslipidemia treatment and raise global sales.
Mismatched prescribing and pharmacy templates for parenteral nutrition can cause errors.
Pharmacist access to prescribing information may change.
FDA approvals, drug indications, and updates
Ivabradine (Corlanor) for heart failure, anthrax immune globulin intravenous (human) (Anthrasil) for inhalational anthrax, and glatiramer acetate (Glatopa) for relapsing forms of multiple sclerosis